This site is intended for healthcare professionals

CheckMate -577, a phase III trial evaluating Opdivo as adjuvant therapy for resected esophageal or gastroesophageal junction cancer, meets primary endpoint of disease-free survival.- BMS

Read time: 1 mins
Last updated:28th Jun 2021
Published:12th Aug 2020
Condition: Oesophageal Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest